Year: 2025
Type: article
Abstract: Human papillomavirus (HPV) remains one of the most prevalent sexually transmitted infections worldwide, with high-risk oncogenic types being closely associated with the development of cervical, anogenital, and oropharyngeal cancers. Despite the availability of effective prophylactic vaccines, the widespread persistence of HPV infection, insufficient immunization coverage in certain regions, and the lack of specific antiviral therapy underscore the need to improve strategies for prevention and treatment.To analyze current approaches to the prevention and treatment of HPV infection with an emphasis on the effectiveness of vaccination, therapeutic interventions, and the potential role of interferon therapy – particularly interferon-α-2b – as a promising immunomodulatory agent.This article presents an analytical review of up-to-date publications, clinical guidelines, and recommendations from World Health Organization, Centers for Disease Control and Prevention, and European Centre for Disease Prevention and Control, along with results from randomized clinical trials regarding HPV prevention and treatment. The evidence base for vaccination, local destructive methods, immunostimulatory therapy, and interferon use is summarized and critically evaluated.Prophylactic vaccination remains the most effective tool in preventing infections caused by high-risk HPV types and the associated precancerous lesions. In the treatment of HPV-induced changes, surgical and destructive methods, immunomodulatory agents, as well as experimental therapeutic vaccines that are in the final stages of clinical trials are used. Interferon-α-2b as an immunomodulator has demonstrated the ability to stimulate antiviral immune responses, promote the regression of cervical intraepithelial neoplasia, and reduce recurrence rates in patients with persistent HPV infection.Modern strategies for HPV management should be comprehensive, combining vaccination, regular screening, timely lesion detection, and personalized treatment approaches, including immunomodulatory therapies. Further clinical studies on the use of interferon-α-2b are warranted to expand therapeutic options for patients with persistent HPV-related disease.
Source: Reproductive health of woman
Authors: D.G. Konkov, O.V. Tykholaz, D.S. Ledin
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4415504635
